NasdaqGS:ABSIBiotechs
Absci (ABSI) Is Up 10.3% After Positive ABS-201 Phase 1 Data And $100M Equity Raise
In late June 2026, Absci Corporation reported positive interim Phase 1 data from its HEADLINE trial of ABS-201 for androgenetic alopecia, showing favorable safety, an estimated half-life of at least 65 days, and progression into multiple ascending dose cohorts, while also completing a US$100.00 million follow-on equity offering of 13,495,277 common shares at US$7.41 each.
The combination of encouraging early data for a long-acting, antibody-based hair loss therapy and fresh equity capital...